Advertisement

Current Medical Science

, Volume 38, Issue 5, pp 785–797 | Cite as

Predictive Value of BRAFV600E Mutation for Lymph Node Metastasis in Papillary Thyroid Cancer: A Meta-analysis

  • Jing-yong Song
  • Shi-ran Sun
  • Fang Dong
  • Tao Huang
  • Bin Wu
  • Jing Zhou
Article
  • 57 Downloads

Abstract

BRAFV600E mutation has been thought to be a valuable molecular marker that may predict a worse prognosis for papillary thyroid cancer (PTC). But whether BRAFV600E mutation is associated with lymph node metastasis (LNM) remains controversial. Different surgical strategies may bring a bias in demonsstrating the association between them. In order to delineate a risk stratification to guide a tailored initial approach to tumors that express BRAFV600E mutation, we performed this meta-analysis by using the articles in which total or near-total thyroidectomy plus bilateral central lymph node dissection was routinely performed to avoid the bias from the surgical strategy. We searched the Medline, Embase and CNKI database for eligible studies from January 2003 to May 2018. Meta-analysis was performed using the STATA 12.0 software. Odds ratios (ORs) and 95% confidence intervals (CIs) were calculated under fixed-effects or randomeffects models. Fifteen clinical studies were included with a total of 4909 PTC patients. Our meta-analysis results reported that BRAFV600E mutation was associated with LNM (OR=1.34; 95% CI: 1.09–1.65; P=0.005), as well as central LNM (OR=1.59; 95% CI: 1.35–1.88; P<0.00001). Moreover, in patients with papillary thyroid microcarcinoma, we also confirmed the predictive value of BRAFV600E mutation for LNM (OR=3.49; 95% CI: 2.02–6.02; P<0.00001). This meta-analysis demonstrates that BRAFV600E mutation is closely related to LNM in PTC patients. The results suggest that BRAFV600E mutation can be considered as a risk factor for LNM in PTC. Moreover, combining BRAFV600E mutation with other risk factors to determine the initial surgical treatment may bring benefits for PTC patients.

Key words

B-Raf proto-oncogene thyroid cancer papillary thyroid carcinoma lymph node metastasis meta-analysis 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Pellegriti G, Frasca F, Regalbuto C, et al. Worldwide increasing incidence of thyroid cancer: update on epidemiology and risk factors. J Cancer Epidemiol, 2013,2013:965212Google Scholar
  2. 2.
    Davies L, Welch HG. Increasing incidence of thyroid cancer in the United States, 1973–2002. JAMA, 2006,295(18):2164–2167Google Scholar
  3. 3.
    Hundahl SA, Fleming ID, Fremgen AM, et al. A National Cancer Data Base report on 53,856 cases of thyroid carcinoma treated in the U. S., 1985–1995 [see commetns]. Cancer, 1998,83(12):2638–2648Google Scholar
  4. 4.
    Loh KC, Greenspan FS, Gee L, et al. Pathological tumor-node-metastasis (pTNM) staging for papillary and follicular thyroid carcinomas: a retrospective analysis of 700 patients. J Clin Endocrinol Metab, 1997,82(11):3553–3562Google Scholar
  5. 5.
    Hundahl SA, Cady B, Cunningham MP, et al. Initial results from a prospective cohort study of 5583 cases of thyroid carcinoma treated in the united states during 1996. U. S. and German Thyroid Cancer Study Group. An American College of Surgeons Commission on Cancer Patient Care Evaluation study. Cancer, 2000,89(1):202–217Google Scholar
  6. 6.
    Sherman SI, Angelos P, Ball DW, et al. Thyroid carcinoma. J Natl Compr Canc Netw, 2005,3(3):404–457Google Scholar
  7. 7.
    Mazzaferri EL, Jhiang SM. Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. Am J Med, 1994,97(5):418–428Google Scholar
  8. 8.
    Nikiforova MN, Kimura ET, Gandhi M, et al. BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas. J Clin Endocrinol Metab, 2003,88(11):5399–5404Google Scholar
  9. 9.
    Kim KH, Kang DW, Kim SH, et al. Mutations of the BRAF gene in papillary thyroid carcinoma in a Korean population. Yonsei Med J, 2004,45(5):818–821Google Scholar
  10. 10.
    Xing M, Westra WH, Tufano RP, et al. BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer. J Clin Endocrinol Metab, 2005,90(12):6373–6379Google Scholar
  11. 11.
    Kim J, Giuliano AE, Turner RR, et al. Lymphatic mapping establishes the role of BRAF gene mutation in papillary thyroid carcinoma. Ann Surg, 2006,244(5):799–804Google Scholar
  12. 12.
    Nakayama H, Yoshida A, Nakamura Y, et al. Clinical significance of BRAF (V600E) mutation and Ki-67 labeling index in papillary thyroid carcinomas. Anticancer Res, 2007,27(5B):3645–3649Google Scholar
  13. 13.
    Kebebew E, Weng J, Bauer J, et al. The prevalence and prognostic value of BRAF mutation in thyroid cancer. Ann Surg, 2007,246(3):466–470; discussion 470–461Google Scholar
  14. 14.
    Lupi C, Giannini R, Ugolini C, et al. Association of BRAF V600E mutation with poor clinicopathological outcomes in 500 consecutive cases of papillary thyroid carcinoma. J Clin Endocrinol Metab, 2007,92(11):4085–4090Google Scholar
  15. 15.
    Rodolico V, Cabibi D, Pizzolanti G, et al. BRAF V600E mutation and p27 kip1 expression in papillary carcinomas of the thyroid <or=1 cm and their paired lymph node metastases. Cancer, 2007,110(6):1218–1226Google Scholar
  16. 16.
    Frasca F, Nucera C, Pellegriti G, et al. BRAF(V600E) mutation and the biology of papillary thyroid cancer. Endocr Relat Cancer, 2008,15(1):191–205Google Scholar
  17. 17.
    Guan H, Ji M, Bao R, et al. Association of high iodine intake with the T1799A BRAF mutation in papillary thyroid cancer. J Clin Endocrinol Metab, 2009,94(5):1612–1617Google Scholar
  18. 18.
    Lee X, Gao M, Ji Y, et al. Analysis of differential BRAF(V600E) mutational status in high aggressive papillary thyroid microcarcinoma. Ann Surg Oncol, 2009,16(2):240–245Google Scholar
  19. 19.
    Oler G, Cerutti JM. High prevalence of BRAF mutation in a Brazilian cohort of patients with sporadic papillary thyroid carcinomas: correlation with more aggressive phenotype and decreased expression of iodide-metabolizing genes. Cancer, 2009,115(5):972–980Google Scholar
  20. 20.
    Gong RX, Zhou Y, Luo SH, et al. An investigation of BRAF mutation in papillary thyroid carcinoma and its clinical value. Zhonghua Yi Xue Yi Chuan Xue Za Zhi (Chinese), 2009,26(3):310–313Google Scholar
  21. 21.
    Basolo F, Torregrossa L, Giannini R, et al. Correlation between the BRAF V600E mutation and tumor invasiveness in papillary thyroid carcinomas smaller than 20 millimeters: analysis of 1060 cases. J Clin Endocrinol Metab, 2010,95(9):4197–4205Google Scholar
  22. 22.
    Sykorova V, Dvorakova S, Ryska A, et al. BRAFV600E mutation in the pathogenesis of a large series of papillary thyroid carcinoma in Czech Republic. J Endocrinol Invest, 2010,33(5):318–324Google Scholar
  23. 23.
    So YK, Son YI, Park JY, et al. Preoperative BRAF mutation has different predictive values for lymph node metastasis according to tumor size. Otolaryngol Head Neck Surg, 2011,145(3):422–427Google Scholar
  24. 24.
    Junfeng LU, Xie N, Yinan JI. The Correlation between BRAFV600E Gene Mutation and p27 Expression and Lymph Node Metastasis of Papillary Thyroid Carcinoma. Hebei Yixue (Chinese), 2011,17:711–714Google Scholar
  25. 25.
    Lee JI, Jang HW, Kim SW, et al. BRAFV600E mutation in fine-needle aspiration aspirates: Association with poorer prognostic factors in larger papillary thyroid carcinomas. Head Neck, 2013,35(4):548–553Google Scholar
  26. 26.
    Gao WL, Wie LL, Chao YG, et al. Prognostic prediction of BRAF(V600E) and its relationship with sodium iodide symporter in classic variant of papillary thyroid carcinomas. Clin Lab, 2012,58(9–10):919–926Google Scholar
  27. 27.
    Chakraborty A, Narkar A, Mukhopadhyaya R, et al. BRAF V600E mutation in papillary thyroid carcinoma: significant association with node metastases and extra thyroidal invasion. Endocr Pathol, 2012,23(2):83–93Google Scholar
  28. 28.
    Guerra A, Fugazzola L, Marotta V, et al. A high percentage of BRAFV600E alleles in papillary thyroid carcinoma predicts a poorer outcome. J Clin Endocrinol Metab, 2012,97(7):2333–2340Google Scholar
  29. 29.
    Joo JY, Park JY, Yoon YH, et al. Prediction of occult central lymph node metastasis in papillary thyroid carcinoma by preoperative BRAF analysis using fine-needle aspiration biopsy: a prospective study. J Clin Endocrinol Metab, 2012,97(11):3996–4003Google Scholar
  30. 30.
    Kim SJ, Lee KE, Myong JP, et al. BRAF V600E mutation is associated with tumor aggressiveness in papillary thyroid cancer. World J Surg, 2012,36(2):310–317Google Scholar
  31. 31.
    Kurtulmus N, Duren M, Ince U, et al. BRAF(V600E) mutation in Turkish patients with papillary thyroid cancer: strong correlation with indicators of tumor aggressiveness. Endocrine, 2012,42(2):404–410Google Scholar
  32. 32.
    Zheng X, Xia T, Lin L, et al. BRAFV600E status and clinical characteristics in solitary and multiple papillary thyroid carcinoma: experience of 512 cases at a clinical center in China. World J Surg Oncol, 2012,10:104Google Scholar
  33. 33.
    Zhao HT, Zhao CQ, Zhang B. Expression and significance of CD44v6, BRAF and Rasp21 in papillary thyroid carcinoma. Zhongguo Zhongliu Linchuang Yu Kangfu (Chinese), 2012,19(4):310–312Google Scholar
  34. 34.
    Yi W, Zhong D, Zou Q. BRAF mutation and papillary thyroid cancer. Zhong Nan Da Xue Xue Bao Yi Xue Ban (Chinese), 2012,37(4):370–373Google Scholar
  35. 35.
    Alzahrani AS, Xing M. Impact of lymph node metastases identified on central neck dissection (CND) on the recurrence of papillary thyroid cancer: potential role of BRAFV600E mutation in defining CND. Endocr Relat Cancer, 2013,20(1):13–22Google Scholar
  36. 36.
    Gouveia C, Can NT, Bostrom A, et al. Lack of association of BRAF mutation with negative prognostic indicators in papillary thyroid carcinoma: the University of California, San Francisco, experience. JAMA Otolaryngol Head Neck Surg, 2013,139(11):1164–1170Google Scholar
  37. 37.
    Howell GM, Nikiforova MN, Carty SE, et al. BRAF V600E mutation independently predicts central compartment lymph node metastasis in patients with papillary thyroid cancer. Ann Surg Oncol, 2013,20(1):47–52Google Scholar
  38. 38.
    Jeong D, Jeong Y, Park JH, et al. BRAF (V600E) mutation analysis in papillary thyroid carcinomas by peptide nucleic acid clamp real-time PCR. Ann Surg Oncol, 2013,20(3):759–766Google Scholar
  39. 39.
    Li C, Aragon Han P, Lee KC, et al. Does BRAF V600E mutation predict aggressive features in papillary thyroid cancer? Results from four endocrine surgery centers. J Clin Endocrinol Metab, 2013,98(9):3702–3712Google Scholar
  40. 40.
    Rossi ED, Martini M, Capodimonti S, et al. BRAF (V600E) mutation analysis on liquid-based cytologyprocessed aspiration biopsies predicts bilaterality and lymph node involvement in papillary thyroid microcarcinoma. Cancer Cytopathol, 2013,121(6):291–297Google Scholar
  41. 41.
    Zheng X, Wei S, Han Y, et al. Papillary microcarcinoma of the thyroid: clinical characteristics and BRAF(V600E) mutational status of 977 cases. Ann Surg Oncol, 2013,20(7):2266–2273Google Scholar
  42. 42.
    Lim JY, Hong SW, Lee YS, et al. Clinicopathologic implications of the BRAF(V600E) mutation in papillary thyroid cancer: a subgroup analysis of 3130 cases in a single center. Thyroid, 2013,23(11):1423–1430Google Scholar
  43. 43.
    Pu YB. Clinical significance of BRAFV600E in papillary thyroid cancer. Shiyong Aizheng Zazhi (Chinese), 2013,28(3):246–248Google Scholar
  44. 44.
    Jiang X, Xie N. Expression and significance of the BRAFV600E-mutated Protein in papillary thyroid carcinoma. Guangdong Yixue (Chinese), 2013,34:931–933Google Scholar
  45. 45.
    Yip L, Nikiforova MN, Yoo JY, et al. Tumor genotype determines phenotype and disease-related outcomes in thyroid cancer: a study of 1510 patients. Ann Surg, 2015,262(3):519–525; discussion 524–515Google Scholar
  46. 46.
    Bastos AU, Oler G, Nozima BH, et al. BRAF V600E and decreased NIS and TPO expression are associated with aggressiveness of a subgroup of papillary thyroid microcarcinoma. Eur J Endocrinol, 2015,173(4):525–540Google Scholar
  47. 47.
    Kim SK, Woo JW, Lee JH, et al. Role of BRAFV600E mutation as an indicator of the extent of thyroidectomy and lymph node dissection in conventional papillary thyroid carcinoma. Surgery, 2015,158(6):1500–1511Google Scholar
  48. 48.
    Shi CL, Sun Y, Ding C, et al. Correlation between the BRAFV600E mutation status and the clinicopathologic features of papillary thyroid carcinoma. Genet Mol Res, 2015,14(3):7377–7385Google Scholar
  49. 49.
    Fraser S, Go C, Aniss A, et al. BRAF(V600E) Mutation is Associated with Decreased Disease-Free Survival in Papillary Thyroid Cancer. World J Surg, 2016,40(7):1618–1624Google Scholar
  50. 50.
    Qu HJ, Qu XY, Hu Z, et al. The synergic effect of BRAF(V600E) mutation and multifocality on central lymph node metastasis in unilateral papillary thyroid carcinoma. Endocr J, 2018,65(1):113–120Google Scholar
  51. 51.
    Namba H, Nakashima M, Hayashi T, et al. Clinical implication of hot spot BRAF mutation, V599E, in papillary thyroid cancers. J Clin Endocrinol Metab, 2003,88(9):4393–4397Google Scholar
  52. 52.
    Yin XL, Zhang GC, Feng LI, et al. BRAFV600E Mutation in Papillary Thyroid Cancer by MASAPCR. Shihezi Daxue Xuebao (Ziran Kexue Ban), 2005,23:552–554Google Scholar
  53. 53.
    Zhu XL, Zhou XY, Zhu XZ. BRAFV599E mutation and RET/PTC rearrangements in papillary thyroid carcinoma. Zhonghua Bing Li Xue Za Zhi (Chinese), 2005,34(5):270–274Google Scholar
  54. 54.
    Kim TY, Kim WB, Song JY, et al. The BRAF mutation is not associated with poor prognostic factors in Korean patients with conventional papillary thyroid microcarcinoma. Clin Endocrinol (Oxf), 2005,63(5):588–593Google Scholar
  55. 55.
    Liu RT, Chen YJ, Chou FF, et al. No correlation between BRAFV600E mutation and clinicopathological features of papillary thyroid carcinomas in Taiwan. Clin Endocrinol (Oxf), 2005,63(4):461–466Google Scholar
  56. 56.
    Adeniran AJ, Zhu Z, Gandhi M, et al. Correlation between genetic alterations and microscopic features, clinical manifestations, and prognostic characteristics of thyroid papillary carcinomas. Am J Surg Pathol, 2006,30(2):216–222Google Scholar
  57. 57.
    Fugazzola L, Puxeddu E, Avenia N, et al. Correlation between B-RAFV600E mutation and clinico-pathologic parameters in papillary thyroid carcinoma: data from a multicentric Italian study and review of the literature. Endocr Relat Cancer, 2006,13(2):455–464Google Scholar
  58. 58.
    Jo YS, Li S, Song JH, et al. Influence of the BRAFV600E mutation on expression of vascular endothelial growth factor in papillary thyroid cancer. J Clin Endocrinol Metab, 2006,91(9):3667–3670Google Scholar
  59. 59.
    Kim TY, Kim WB, Rhee YS, et al. The BRAF mutation is useful for prediction of clinical recurrence in lowrisk patients with conventional papillary thyroid carcinoma. Clin Endocrinol (Oxf), 2006,65(3):364–368Google Scholar
  60. 60.
    Lee JH, Lee ES, Kim YS, et al. BRAF mutation and AKAP9 expression in sporadic papillary thyroid carcinomas. Pathology, 2006,38(3):201–204Google Scholar
  61. 61.
    Abrosimov A, Saenko V, Rogounovitch T, et al. Different structural components of conventional papillary thyroid carcinoma display mostly identical BRAF status. Int J Cancer, 2007,120(1):196–200Google Scholar
  62. 62.
    Costa AM, Herrero A, Fresno MF, et al. BRAF mutation associated with other genetic events identifies a subset of aggressive papillary thyroid carcinoma. Clin Endocrinol (Oxf), 2008,68(4):618–634Google Scholar
  63. 63.
    Elisei R, Ugolini C, Viola D, et al. BRAF(V600E) mutation and outcome of patients with papillary thyroid carcinoma: a 15-year median follow-up study. J Clin Endocrinol Metab, 2008,93(10):3943–3949Google Scholar
  64. 64.
    Niu W, Luo YQ, Chen LR. Clinical significance of BRAF mutation and expression in papillary thyroid carcinoma. Journal of Practical Oncology, 2008,23(6):519–523Google Scholar
  65. 65.
    Mi Z, Wang A, Zhao Z, et al. Study of BRAFV600E mutation in papillary thyroid cancer. Shaanxi Med J (Chinese), 2008,37:1471–1477Google Scholar
  66. 66.
    Ito Y, Yoshida H, Maruo R, et al. BRAF mutation in papillary thyroid carcinoma in a Japanese population: its lack of correlation with high-risk clinicopathological features and disease-free survival of patients. Endocr J, 2009,56(1):89–97Google Scholar
  67. 67.
    Kwak JY, Kim EK, Chung WY, et al. Association of BRAFV600E mutation with poor clinical prognostic factors and US features in Korean patients with papillary thyroid microcarcinoma. Radiology, 2009,253(3):854–860Google Scholar
  68. 68.
    Zang X, Chen J, Lin H, et al. The research of BRAFV600E mutation in papillary thyroid cancer. Xiandai Shiyong Yixue (Chinese), 2009,21:1296-1297Google Scholar
  69. 69.
    Lin KL, Wang OC, Zhang XH, et al. The BRAF mutation is predictive of aggressive clinicopathological characteristics in papillary thyroid microcarcinoma. Ann Surg Oncol, 2010,17(12):3294–3300Google Scholar
  70. 70.
    Stanojevic B, Dzodic R, Saenko V, et al. Mutational and clinico-pathological analysis of papillary thyroid carcinoma in Serbia. Endocr J, 2011,58(5):381–393Google Scholar
  71. 71.
    Eloy C, Santos J, Soares P, et al. The preeminence of growth pattern and invasiveness and the limited influence of BRAF and RAS mutations in the occurrence of papillary thyroid carcinoma lymph node metastases. Virchows Arch, 2011,459(3):265–276Google Scholar
  72. 72.
    Pelizzo MR, Boschin IM, Barollo S, et al. BRAF analysis by fine needle aspiration biopsy of thyroid nodules improves preoperative identification of papillary thyroid carcinoma and represents a prognostic factor. A mono-institutional experience. Clin Chem Lab Med, 2011,49(2):325–329Google Scholar
  73. 73.
    Zheng X, Xia T, Lin L, et al. BRAFV600E Mutational Status and Ciinico-biological Characteristics of Multifocal Papillary Thyroid Carcinomas. Zhongguo Zhongliu Linchuang (Chinese), 2011,38:1326–1329Google Scholar
  74. 74.
    Dai Y, Li B, Wang S. The association between BRAF mutation and lymph node metastasis in papillary thyroid cancer. Zhongguo Yixue Chuangxin (Chinese), 2011,8(31):29–30Google Scholar
  75. 75.
    Paulson L, Shindo M, Schuff K, et al. The role of molecular markers and tumor histological type in central lymph node metastasis of papillary thyroid carcinoma. Arch Otolaryngol Head Neck Surg, 2012,138(1):44–49Google Scholar
  76. 76.
    Koperek O, Kornauth C, Capper D, et al. Immunohistochemical detection of the BRAF V600Emutated protein in papillary thyroid carcinoma. Am J Surg Pathol, 2012,36(6):844–850Google Scholar
  77. 77.
    Ahn D, Park JS, Sohn JH, et al. BRAFV600E mutation does not serve as a prognostic factor in Korean patients with papillary thyroid carcinoma. Auris Nasus Larynx, 2012,39(2):198–203Google Scholar
  78. 78.
    Kurt B, Yalcin S, Alagoz E, et al. The relationship of the BRAF(V600E) mutation and the established prognostic factors in papillary thyroid carcinomas. Endocr Pathol, 2012,23(3):135–140Google Scholar
  79. 79.
    Lee KC, Li C, Schneider EB, et al. Is BRAF mutation associated with lymph node metastasis in patients with papillary thyroid cancer? Surgery, 2012,152(6):977–983Google Scholar
  80. 80.
    Lee ST, Kim SW, Ki CS, et al. Clinical implication of highly sensitive detection of the BRAFV600E mutation in fine-needle aspirations of thyroid nodules: a comparative analysis of three molecular assays in 4585 consecutive cases in a BRAF V600E mutation-prevalent area. J Clin Endocrinol Metab, 2012,97(7):2299–2306Google Scholar
  81. 81.
    Nam JK, Jung CK, Song BJ, et al. Is the BRAF(V600E) mutation useful as a predictor of preoperative risk in papillary thyroid cancer? Am J Surg, 2012,203(4):436–441Google Scholar
  82. 82.
    Sassolas G, Hafdi-Nejjari Z, Ferraro A, et al. Oncogenic alterations in papillary thyroid cancers of young patients. Thyroid, 2012,22(1):17–26Google Scholar
  83. 83.
    Ulisse S, Baldini E, Sorrenti S, et al. In papillary thyroid carcinoma BRAFV600E is associated with increased expression of the urokinase plasminogen activator and its cognate receptor, but not with diseasefree interval. Clin Endocrinol (Oxf), 2012,77(5):780–786Google Scholar
  84. 84.
    Xiao-Qiang LI, Zhang HZ, Jiang ZM, et al. Expression of BRAF gene and its significance in papillary thyroid carcinoma. J Clin Exp Pathol, 2012,28:991–995Google Scholar
  85. 85.
    Xia T, Chuanxiang HU, Zhao J, et al. BRAFV600E Mutation in Papillary Thyroid Carcinoma. Chin J Clin Oncol (Chinese), 2012,7(2):439–443(435)Google Scholar
  86. 86.
    Kim YS, Kim JS, Bae JS, et al. Clinical implication of the BRAFV600E mutation in papillary thyroid carcinoma. World J Surg Oncol, 2013,11:99Google Scholar
  87. 87.
    Fernandez IJ, Piccin O, Sciascia S, et al. Clinical significance of BRAF mutation in thyroid papillary cancer. Otolaryngol Head Neck Surg, 2013,148(6):919–925Google Scholar
  88. 88.
    Gandolfi G, Sancisi V, Torricelli F, et al. Allele percentage of the BRAF V600E mutation in papillary thyroid carcinomas and corresponding lymph node metastases: no evidence for a role in tumor progression. J Clin Endocrinol Metab, 2013,98(5):E934–E942Google Scholar
  89. 89.
    McKelvie PA, Chan F, Yu Y, et al. The prognostic significance of the BRAF V600E mutation in papillary thyroid carcinoma detected by mutation-specific immunohistochemistry. Pathology, 2013,45(7):637–644Google Scholar
  90. 90.
    Choi SY, Park H, Kang MK, et al. The relationship between the BRAF(V600E) mutation in papillary thyroid microcarcinoma and clinicopathologic factors. World J Surg Oncol, 2013,11:291Google Scholar
  91. 91.
    Zagzag J, Pollack A, Dultz L, et al. Clinical utility of immunohistochemistry for the detection of the BRAF v600e mutation in papillary thyroid carcinoma. Surgery, 2013,154(6):1199–1204; discussion 1204–1195Google Scholar
  92. 92.
    Gong Y, Gong R, Yang J, et al. The association between BRAF mutation and clinicopathological characteristics and its clinical implication in papillary thyroid cancer. Sichuan Da Xue Xue Bao Yi Xue Ban (Chinese), 2013,44:662–665Google Scholar
  93. 93.
    Zheng L, Hu X. Significance of expressions of HBME-1, Galectin-3, CK19 and BRAF mutation in papillary thyroid carcinoma. Anhui Yike Daxue Xuebao (Chinese), 2013,48(4):401–405Google Scholar
  94. 94.
    Danilovic DL, Lima EU, Domingues RB, et al. Preoperative role of BRAF in the guidance of the surgical approach and prognosis of differentiated thyroid carcinoma. Eur J Endocrinol, 2014,170(4):619–625Google Scholar
  95. 95.
    Walczyk A, Kowalska A, Kowalik A, et al. The BRAF(V600E) mutation in papillary thyroid microcarcinoma: does the mutation have an impact on clinical outcome? Clin Endocrinol (Oxf), 2014,80(6):899–904Google Scholar
  96. 96.
    Walts AE, Mirocha JM, Bose S. Follicular variant of papillary thyroid carcinoma (FVPTC): histological features, BRAF V600E mutation, and lymph node status. J Cancer Res Clin Oncol, 2015,141(10):1749–1756Google Scholar
  97. 97.
    Park VY, Kim EK, Lee HS, et al. Real-Time PCR Cycle Threshold Values for the BRAFV600E Mutation in Papillary Thyroid Microcarcinoma May Be Associated With Central Lymph Node Metastasis: A Retrospective Study. Medicine (Baltimore), 2015,94(28):e1149Google Scholar
  98. 98.
    Czarniecka A, Kowal M, Rusinek D, et al. The Risk of Relapse in Papillary Thyroid Cancer (PTC) in the Context of BRAFV600E Mutation Status and Other Prognostic Factors. PLoS One, 2015,10(7):e0132821Google Scholar
  99. 99.
    Lin JD, Fu SS, Chen JY, et al. Clinical Manifestations and Gene Expression in Patients with Conventional Papillary Thyroid Carcinoma Carrying the BRAF(V600E) Mutation and BRAF Pseudogene. Thyroid, 2016,26(5):691–704Google Scholar
  100. 100.
    Sun J, Zhang J, Lu J, et al. BRAF V600E and TERT Promoter Mutations in Papillary Thyroid Carcinoma in Chinese Patients. PLoS One, 2016,11(4):e0153319Google Scholar
  101. 101.
    Park VY, Kim EK, Moon HJ, et al. The thyroid imaging reporting and data system on US, but not the BRAFV600E mutation in fine-needle aspirates, is associated with lateral lymph node metastasis in PTC. Medicine (Baltimore), 2016,95(29):e4292Google Scholar
  102. 102.
    Fakhruddin N, Jabbour M, Novy M, et al. BRAF and NRAS Mutations in Papillary Thyroid Carcinoma and Concordance in BRAF Mutations Between Primary and Corresponding Lymph Node Metastases. Sci Rep, 2017,7(1):4666Google Scholar
  103. 103.
    Tufano RP, Teixeira GV, Bishop J, et al. BRAF mutation in papillary thyroid cancer and its value in tailoring initial treatment: a systematic review and meta-analysis. Medicine (Baltimore), 2012,91(5):274–286Google Scholar
  104. 104.
    Kim TH, Park YJ, Lim JA, et al. The association of the BRAF(V600E) mutation with prognostic factors and poor clinical outcome in papillary thyroid cancer: a meta-analysis. Cancer, 2012,118(7):1764–1773Google Scholar
  105. 105.
    Zhang Q, Liu SZ, Zhang Q, et al. Meta-Analyses of Association Between BRAF(V600E) Mutation and Clinicopathological Features of Papillary Thyroid Carcinoma. Cell Physiol Biochem, 2016,38(2):763–776Google Scholar
  106. 106.
    Ma B, Wang Y, Yang S, et al. Predictive factors for central lymph node metastasis in patients with cN0 papillary thyroid carcinoma: A systematic review and meta-analysis. Int J Surg, 2016,28:153–161Google Scholar
  107. 107.
    Liu C, Chen T, Liu Z. Associations between BRAF(V600E) and prognostic factors and poor outcomes in papillary thyroid carcinoma: a metaanalysis. World J Surg Oncol, 2016,14(1):241Google Scholar
  108. 108.
    Lee JH, Lee ES, Kim YS. Clinicopathologic significance of BRAFV600E mutation in papillary carcinomas of the thyroid: a meta-analysis. Cancer, 2007,110(1):38–46Google Scholar
  109. 109.
    Zimmermann AK, Camenisch U, Rechsteiner MP, et al. Value of immunohistochemistry in the detection of BRAF(V600E) mutations in fine-needle aspiration biopsies of papillary thyroid carcinoma. Cancer Cytopathol, 2014,122(1):48–58Google Scholar
  110. 110.
    Fisher KE, Neill SG, Ehsani L, et al. Immunohistochemical investigation of BRAF p. V600E mutations in thyroid carcinoma using 2 separate BRAF antibodies. Appl Immunohistochem Mol Morphol, 2014,22(8):562–567Google Scholar
  111. 111.
    Stulak JM, Grant CS, Farley DR, et al. Value of preoperative ultrasonography in the surgical management of initial and reoperative papillary thyroid cancer. Arch Surg, 2006,141(5):489–494; discussion 494–486Google Scholar
  112. 112.
    Vergez S, Sarini J, Percodani J, et al. Lymph node management in clinically node-negative patients with papillary thyroid carcinoma. Eur J Surg Oncol, 2010,36(8):777–782Google Scholar
  113. 113.
    Conzo G, Pasquali D, Bellastella G, et al. Total thyroidectomy, without prophylactic central lymph node dissection, in the treatment of differentiated thyroid cancer. Clinical retrospective study on 221 cases. Endocrine, 2013,44(2):419–425Google Scholar
  114. 114.
    Barczynski M, Konturek A, Stopa M, et al. Prophylactic central neck dissection for papillary thyroid cancer. Br J Surg, 2013,100(3):410–418Google Scholar
  115. 115.
    Chisholm EJ, Kulinskaya E, Tolley NS. Systematic review and meta-analysis of the adverse effects of thyroidectomy combined with central neck dissection as compared with thyroidectomy alone. Laryngoscope, 2009,119(6):1135–1139Google Scholar
  116. 116.
    Glover AR, Gundara JS, Norlen O, et al. The pros and cons of prophylactic central neck dissection in papillary thyroid carcinoma. Gland Surg, 2013,2(4):196–205Google Scholar
  117. 117.
    Rosenbaum MA, McHenry CR. Central neck dissection for papillary thyroid cancer. Arch Otolaryngol Head Neck Surg, 2009,135(11):1092–1097Google Scholar
  118. 118.
    Yu XM, Wan Y, Sippel RS, et al. Should all papillary thyroid microcarcinomas be aggressively treated? An analysis of 18,445 cases. Ann Surg, 2011,254(4):653–660Google Scholar
  119. 119.
    Ward LS, Morari EC, Leite JL, et al. Identifying a risk profile for thyroid cancer. Arq Bras Endocrinol Metabol, 2007,51(5):713–722Google Scholar
  120. 120.
    Zhou YL, Zhang W, Gao EL, et al. Preoperative BRAF mutation is predictive of occult contralateral carcinoma in patients with unilateral papillary thyroid microcarcinoma. Asian Pac J Cancer Prev, 2012,13(4):1267–1272Google Scholar

Copyright information

© Huazhong University of Science and Technology 2018

Authors and Affiliations

  1. 1.Department of Breast and Thyroid Surgery, Union Hospital, Tongji Medical CollegeHuazhong University of Science and TechnologyWuhanChina
  2. 2.Department of Gastrointestinal SurgeryHainan Cancer HospitalHaikouChina
  3. 3.Department of Hepatobiliary Surgery, Union Hospital, Tongji Medical CollegeHuazhong University of Science and TechnologyWuhanChina
  4. 4.Department of Orthopaedics Surgery, Union Hospital, Tongji Medical CollegeHuazhong University of Science and TechnologyWuhanChina

Personalised recommendations